Skip to content

Study on the utility of ultrathin bronchoscopy in the diagnosis of non-tuberculous mycobacterial pulmonary disease

Study on the utility of ultrathin bronchoscopy in the diagnosis of non-tuberculous mycobacterial pulmonary disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1052240011
Enrollment
40
Registered
2024-04-17
Start date
2024-02-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary nontuberculous mycobacterial disease nontuberculous mycobacterial infection

Interventions

None listed

Sponsors

Tomoya Kawaguchi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients with clinically suspected pulmonary non-tuberculous mycobacterial infection such as nodular or cavernous shadows or other characteristic images on chest CT 2) Patients scheduled for bronchoscopy for 1 3) Patients who are 20 years of age or older at the time of the bronchoscopy 4) Patients who have given written consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1) Patients with sputum culture positive for Mycobacterium tuberculosis from two or more sputum samples. 2) Patients with a history of treatment for pulmonary non-tuberculous Mycobacterium tuberculosis in the past. 3) Patients with confirmed or clinically suspected pulmonary tuberculosis. 4) Patients with poorly controlled complications (unstable angina, acute myocardial infarction, severe bronchial asthma, active pulmonary infection, heart failure, bleeding tendency, cerebral infarction, etc.) or psychiatric disorders or psychiatric symptoms that interfere with daily life, which make participation in the study difficult. 5) Other cases that the investigator deems inappropriate for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
Positivity rate (number of culture-positive cases/number of cases in the analyzed population)

Secondary

MeasureTime frame
True positive rate number of culture-positive cases/(number of cases in the analyzed population - number of true negative cases). The true positivity rate is defined as the ratio of the number of culture-positive cases to the number of true-negative cases (see below), which is subtracted from the number of cases in the analysis population defined as the positivity rate for the primary endpoint. True negative cases: Cases that are culture-negative in various specimens and meet either of the following conditions: 1) or 2). In such cases, improvement or final diagnosis should also be noted in the report. 1) Patients who have been treated with no treatment or treatment other than pulmonary non-tuberculous mycobacteriosis, and the negative result of CT scan of the chest has improved after 6 months. 2) Cases in which a diagnosis other than pulmonary non-tuberculous Mycobacterium tuberculosis was made within 6 months. The results of smear test of each specimen (aspirated sputum, brush specimen, transbronchial biopsy specimen, and bronchial lavage fluid) collected by ultrafine bronchoscopy. Nucleic acid amplification test of each specimen collected by ultrafine bronchoscope (aspirated sputum, brush swab specimen, transbronchial biopsy specimen, and bronchial lavage fluid) Sensitivity, specificity, positive predictive value, negative predictive value, and positive predictive value calculated from the test results of each specimen. Results of tissue and cell diagnosis of bronchial biopsy Total examination time Amount of sedatives and analgesics used during the test Safety

Contacts

Public ContactUeda Takahiro

Graduate School of Medicine, Osaka Metropolitan University

mhe.msjh.kmu@gmail.com+81-6-6645-3916

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026